Meet the newest antidepressant
Meet the newest antidepressant: dextromethorphan/buproprion ...
Meet the newest antidepressant: dextromethorphan/buproprion (Auvelity) ... Dextromethorphan/bupropion (Auvelity), was recently approved by the ...
The Newest Antidepressants Offering Hope - Neuro Wellness Spa
Exxua was approved in 2023 and will be available to the public in 2024. This new antidepressant introduces a unique mechanism of action in ...
Newest Antidepressants: Brexanolone, Esketamine, Agomelatine
Depression typically involves low BDNF levels, and your brain may have difficulty adapting to changes. Esketamine helps restore BDNF levels, ...
Gepirone: After Nearly Two Decades, FDA Approves This Not-So ...
Last week, the FDA approved gepirone hydrochloride ER for the treatment of major depressive disorder. This not-so-new antidepressant is in ...
Esketamine for Treatment-Resistant Depression
There's hope for people with treatment-resistant depression. Learn about esketamine, an antidepressant that helps when other medications aren't effective.
New Drug for Major Depression Is Approved by FDA - Everyday Health
Gepirone, sold under the brand name Exxua, does not cause sexual dysfunction or weight gain, unlike other antidepressants.
New antidepressants: tackling treatment resistant depression
After a long period of stagnation, in which no new classes of antidepressants were approved, the U.S. Food and Drug Administration (FDA) ...
FDA approves new ER antidepressant
Lauren Howell, PharmD In September 2023, FDA approved Exxua (gepirone), a new extended-release antidepressant. When Exxua comes to the...
'A wild west': Patients seek new depression treatments with different ...
More recently, in October 2023, the FDA approved Exxua (gepirone hydrochloride, Fabre-Kramer Pharmaceuticals) for adults with major depressive ...
New Antidepressants: What Are They and More - Psych Central
New antidepressants, like esketamine and brexanolone, have a fresh approach to treating depression and offer options when other medications may not work.
Depression's new directions - Mayo Clinic Press
Esketamine (Spravato) is a fast-acting antidepressant that was approved by the Food and Drug Administration (FDA) in 2019 for people with ...
FDA Approves Auvelity, a New Medication for Clinical Depression
It is the first drug to treat major depressive disorder that works within a week of taking it and is the first new pill to treat depression ...
New depression drugs are bringing hope to a long-stagnant field
The agent, called Lilly 110140, altered chemical activity in the brain linked to depression. It tested as mildly effective, had fewer side ...
FDA approves new nasal spray medication for treatment-resistant ...
FDA approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults with ...
FDA Approves Auvelity, Faster-Acting Antidepressant - Verywell Mind
The FDA has approved Auvelity, a new antidepressant that may treat symptoms faster than other medications. ... Meet Our Review Board · About ...
Exploring New and Old Worldviews on Depression - WCG Clinical
What happened? The US FDAapproved esketamine. It was a landmark moment: Approval of this new rapid-acting antidepressant formulated for intranasal use marked ...
The clinical utility of newer antidepressant agents - PubMed Central
Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 oral antidepressants ...
Fast Acting Antidepressants | Neuro Wellness Spa
... meet the urgent need for fast acting antidepressants ... Newer antidepressant medications such as Auvelity, and some SSRIs, such as Zoloft ...
New antidepressants for old people?: The evidence that newer ...
Drop out rates in the trials comparing older antidepressants with new ones are available for sertraline versus amitriptyline (48% v 49%), paroxetine versus ...
Esketamine for Treatment-Resistant Depression — First FDA ...
Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class · Notes · Supplementary Material · References.